Enlonstobart

Monoclonal antibody

Also known as SG001

Approvedregulatory verdict

Evidence outlook

Approved: Conditional approval: recurrent or metastatic cervical cancer, PD-L1 positive (CPS at... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Cervical Cancer · Phase 3 · investigational in the US

Also approved (1)
CN
  • Conditional approval: recurrent or metastatic cervical cancer, PD-L1 positive (CPS at least 1), after failure of platinum-based chemotherapy (brand Enshuxing)
Product first approved 2024www1.hkexnews.hk

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (5)
Cervical Cancer
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07925021 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-11-06 – 2030-12-01 · Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma
What this study did
Phase 2/3 (4)
Non-Small Cell Lung Cancer
NCT07662811 · Shanghai Chest Hospital
2026-06-01 – 2029-12-31 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07332533 · Shanghai JMT-Bio Inc.
2025-12-30 – 2032-12-31 · HER2-positive Gastric Cancer
What this study did
NCT07585279 · Hebei Medical University Fourth Hospital
2026-05-20 – 2032-02-28 · Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line
What this study did
NCT07251062 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2025-12-30 – 2030-12-30 · Esophageal Squamous Cell Carcinoma
What this study did
Phase 2 (13)
Cervical Cancer
NCT06981858 · Chongqing University Cancer Hospital
2025-05-15 – 2029-02-01 · LOCALLY ADVANCED CERVICAL CANCERS
What this study did
NCT04886700 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2021-07-31 – 2023-12-31 · Uterine Cervical Cancer
What this study did
Other / comorbidity
NCT07810114 · Fudan University
2026-08-28 – 2030-12-01 · Rectal Cancer
What this study did
NCT07448077 · Hebei Medical University Fourth Hospital
2026-03-01 – 2030-06-30 · Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer
What this study did
NCT07183865 · Fudan University
2025-03-09 – 2030-03-09 · Locally Recurrent Rectal Cancer
What this study did
NCT06998771 · Shanghai JMT-Bio Inc.
2025-06-15 – 2029-12-31 · HER2-positive Gastric Cancer
What this study did
NCT07714668 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-08-13 – 2029-08-31 · Ovarian Cancer, Recurrent Ovarian Cancer
What this study did
NCT07254585 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2025-12-12 – 2028-12-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06989671 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2025-08-30 – 2028-07-30 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06089330 · Shanghai JMT-Bio Inc.
2024-01 – 2024-12 · Metastatic Colorectal Cancer (mCRC)
What this study did
NCT04983550 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2021-09 – 2024-01 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT05068141 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2021-10-01 – 2023-10-01 · Triple Negative Breast Cancer
What this study did
NCT05009953 · CSPC Ouyi Pharmaceutical Co., Ltd.
2021-09-01 – 2023-01-16 · Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
What this study did
Phase 1/2 (4)
Other / comorbidity
NCT07282509 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2025-12-23 – 2029-02-03 · Advanced Hepatocellular Carcinoma (HCC)
What this study did
NCT06136988 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2023-12 – 2028-04 · Locally Advanced Unresectable Esophageal Squamous Carcinoma
What this study did
NCT07288814 · Sun Yat-Sen University Cancer Center
2025-12-08 – 2027-12-31 · Relapsed or Refractory Peripheral T Cell Lymphoma
What this study did
NCT06132217 · Shanghai Runshi Pharmaceutical Technology Co., Ltd
2024-01-30 – 2027-01-30 · Advanced Solid Tumor
What this study did
Phase 1 (1)
Non-Small Cell Lung Cancer
NCT03852823 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2019-05-23 – 2023-03 · Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma, Lymphoma, Non-Small-Cell Lung Cancer
What this study did
Phase 4 (1)
Cervical Cancer
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1/2 (1)
Other / comorbidity
NCT06682611 · Shanghai Runshi Pharmaceutical Technology Co., Ltd
2024-11-13 – 2027-11-13 · Unresectable Locally Advanced or Metastatic Solid Tumors
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1/2 (2)
Other / comorbidity
NCT07622225 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-05-29 – 2030-01-31 · Advanced Solid Tumors
What this study did
NCT05508659 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2022-09-20 – 2025-03-20 · Advanced Solid Tumors
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, 10 of them ahead of this one.

This drug's own stage for Cervical Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Enlonstobart: this drugPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)ApprovedAntibody–drug conjugateTissue Factor (TF)Partial signal
NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7)
NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sutantatug EnvedotinPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
ALE.P02
Phase 1/2(overall)
Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(19 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Enlonstobart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1/2Relapsed or Refractory Peripheral T Cell LymphomaNot yet recruiting
Est. primary completion 2026-12-31 · NCT07288814 · CT.gov ↗
What to watch
2027 (6)
January 2027 (1)
Phase 1/2Advanced Solid TumorNot yet recruiting
Est. primary completion 2027-01-30 · NCT06132217 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1/2Locally Advanced Unresectable Esophageal Squamous CarcinomaNot yet recruiting
Est. primary completion 2027-04 · NCT06136988 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT07633873 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Rectal CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT07810114 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-30 · NCT06989671 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07662811 · CT.gov ↗
What to watch
2028 (4)
April 2028 (1)
Phase 2Ovarian Cancer, Recurrent Ovarian CancerRecruiting
Est. primary completion 2028-04-30 · NCT07714668 · CT.gov ↗
What to watch
June 2028 (3)
Phase 1/2Advanced Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2028-06-26 · NCT07282509 · CT.gov ↗
What to watch
Phase 2HER2-positive Gastric CancerNot yet recruiting
Est. primary completion 2028-06-30 · NCT06998771 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT07254585 · CT.gov ↗
What to watch
2029 (5)
February 2029 (1)
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2029-02-01 · NCT06981858 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-30 · NCT07672223 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2029-10-01 · NCT07925021 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-12-30 · NCT07251062 · CT.gov ↗
What to watch
Phase 3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-12-30 · NCT07924111 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
Phase 2Locally Recurrent Rectal CancerRecruiting
Est. primary completion 2030-03-09 · NCT07183865 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
Phase 2/3Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-LineNot yet recruiting
Est. primary completion 2031-02-28 · NCT07585279 · CT.gov ↗
What to watch
2032 (1)
June 2032 (1)
Phase 2/3HER2-positive Gastric CancerNot yet recruiting
Est. primary completion 2032-06-30 · NCT07332533 · CT.gov ↗
What to watch

See the full readout calendar ↗